Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial.

Richard J ZeifmanNikhita SinghalRafael G Dos SantosRafael F SanchesFlávia de Lima OsórioJaime E C HallakCory R Weissman

Published in: Psychopharmacology (2020)

When administered in the appropriate context, ayahuasca may lead to rapid and sustained reductions in suicidality among individuals with MDD. Randomized, double-blind studies with larger sample sizes are needed to confirm this early finding.

Keyphrases

major depressive disorder
double blind
phase iii
placebo controlled
phase ii
bipolar disorder
clinical trial
open label
study protocol
loop mediated isothermal amplification
randomized controlled trial
case control